Sotera Health Raises FY 2026 Outlook After Strong Q2, Hits Leverage Target
SHC sits 63% above its 52-week low of $11.
Summary
Sotera Health reported strong Q2 2026 results with high-single-digit constant currency revenue growth across all three segments. Sterigenics revenue rose 7.0%, Nordion surged 16.7%, and Nelson Labs grew 5.4%. Overall Q2 revenue rose 9.2%, beating estimates. Adjusted EBITDA margin expanded to 51.6%. The company raised its full-year 2026 outlook, citing first-half momentum and confidence in the remainder of the year. Net leverage improved to 3.0x, hitting the long-term target range, and the final private equity sponsor secondary offering was completed, removing sponsor overhang. This follows the Q1 2026 beat and favorable litigation rulings in May, reinforcing a positive trajectory. The raised guidance and balance sheet milestone are material positives that should drive upward estimate revisions.
Updates
· SEC 8-K — Q2 net income was $54 million, or $0.19 per diluted share, compared to $8 million, or $0.03 per share, a year earlier. Adjusted EPS rose 30% to $0.26. Full-year 2026 net revenues guidance raised to $1.236 billion to $1.254 billion and Adjusted EBITDA to $634 million to $643 million.
At the time of this announcement, SHC was trading at $17.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1B. The 52-week trading range was $11.00 to $19.85. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.